Clinical trial · Interventional
Cryoablation of Brain Neoplasm
Safety and Feasibility of the Use of Cryoablation in Patients With Brain Tumors
NCT06753617CI-TRIAL-00084224enrolling by invitationN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will investigate the use of safety and feasibility of cryoablation in brain tumors
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Brain Neoplasm | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cryoablation of brain neoplasm | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cryoablation Treatment Group
- description
- All patients enrolled in this study will undergo cryoablation as part of their surgical tumor resection procedure. The intervention will be integrated into the standard surgical approach.
- interventionNames
- Procedure: Cryoablation of brain neoplasm
Primary outcomes (3)
- measure
- Safety: Incidence and Severity of Complications and Morbidity During the Study Period
- timeFrame
- From enrollment to the end of the study, with a minimum follow-up of 3 months. Complications such as bleeding, infection, epilepsy, brain edema, neurological deficit, and death will be evaluated, with safety assessed up to 12 months post-surgery.
- description
- Complications \& morbidity during the entire study period as decided by the treating physician. Severity and frequency of the following complications: * Postoperative intracranial bleeding * Wound infection * Epilepsy * Brain edema * Neurological deficit (paresis/plegia) * Aphasia * Death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years * Tumor suspected as glioma (1. Astrocytoma, IDH mutant 2. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted 3. Glioblastoma, IDH-wildtype), meningioma (WHO gr. 1 and gr 2), or brain metastasis based on preliminary diagnosis for which the patient will undergo surgery * Supratentorial or infratentorial localization * Safe trajectory/trajectories possible for ablation of at least 70% of the tumor, avoiding eloquent structures * Karnofsky performance scale 70 or more * Sufficient knowledge of the Dutch language to understand the study documents (in the judgement of the attending physician or researcher) * Written Informed consent Exclusion Criteria: * \<18 years or \>80 years * Tumor diameter bigger than 10 cm * Unsafe trajectory (eloquent structures could be damaged) * Pregnancy * Contra-indication for general anesthesia
References
Publications (0)
Data not yet available
No reference posted for this study.